Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 Febrero 2024 - 3:05PM
Business Wire
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a
focus on building an aesthetic portfolio of consumer brands, today
reported the grant of an aggregate of 15,101 restricted stock units
(RSUs) of the company’s common stock to 7 newly hired non-executive
employees of the company. The awards were approved by the
compensation committee of the company’s board of directors under
Evolus’ 2023 Inducement Incentive Plan, with a grant date and a
vesting commencement date of February 7, 2024, as an inducement
material to the new employees entering into employment with Evolus
in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest 25% on each annual anniversary of the vesting
commencement date. The awards are subject to the terms and
conditions of the 2023 Inducement Incentive Plan and the terms and
conditions of the RSU agreement covering the grant, including
requirements to remain continuously employed on each vesting
date.
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a performance beauty company evolving
the aesthetic neurotoxin market for the next generation of beauty
consumers through its unique, customer-centric business model and
innovative digital platform. Our mission is to become a global,
multi-product aesthetics company based on our flagship product,
Jeuveau® (prabotulinumtoxinA-xvfs), globally licensed under the
brand name Nuceiva®. The product is manufactured in a
state-of-the-art facility using Hi-Pure™ technology. Evolus is
expanding its product portfolio having entered into a definitive
agreement to be the exclusive U.S. distributor of Evolysse™, a line
of five unique dermal fillers currently in late-stage development.
Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram
or Facebook.
Jeuveau®, Nuceiva®, and Evolysse™ are trademarks of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd. Estyme®
is a trademark of Symatese Aesthetics S.A.S.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240209938370/en/
Investors: Nareg Sagherian Vice
President, Head of Global Investor Relations and Corporate
Communications Tel: 248-202-9267 Email: ir@evolus.com
Media: Email: media@evolus.com
Evolus (NASDAQ:EOLS)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Evolus (NASDAQ:EOLS)
Gráfica de Acción Histórica
De May 2023 a May 2024